clinical

Phase 3

• Conditions: C75.0; Thyroid cancer.; Malignant neoplasm of parathyroid gland

• Registration Number: IRCT20220212054005N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

patient informed satisfaction
dose received by patients should be between 150 to 200 mci
patients should be 24 to 79 years old

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TNF factor. Timepoint: evaluate the inflammatory factor ,blood samples are taken and evaluated once before the radiopharmaceutical and once a week after the treatment. Method of measurement: Eliza reader.